logo-loader

Q BioMed welcomes study that highlights the safety and efficacy of Uttroside-B chemotherapeutic

Published: 16:08 26 Jul 2022 EDT

Q BioMed Inc. (OTCQB:QBIO) CEO Denis Corin says a new study that shows the superior safety and efficacy of its Uttroside-B chemotherapeutic versus FDA-approved drug Sorafenib adds weight to the promise of an effective therapeutic for a patient population that desperately needs better and more treatment options.

Corin told Proactive that the study provides additional data for Q BioMed to present to potential partners.

"Our objective with this asset has always been to develop it and hopefully partner it with large pharma who are interested in this space," Corin added.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 52 minutes ago